ecancermedicalscience

Research

Is there a role for 'modified VAD' in the treatment of multiple myeloma?

4 Jun 2009
A Agazzi, S Sammassimo, D Laszlo, SJ Liptrott, R Cascio, A Alietti, C Rabascio, P Mancuso, G Pruneri, G Martinelli

VAD, (Vincristine, Doxorubicin and Dexamethasone) was initially proposed as a salvage therapy for myeloma patients in whom prior alkylating agent therapy failed, although in recent years VAD has been surpassed by novel combination therapies with new biological agents such as thalidomide (and its derivative, lenalidomide) and bortezomib. After the excellent results obtained by the novel agents, VAD can no longer be proposed in preparation to autologous transplantation, although there are still indications that VAD remains useful and clinically relevant in the initial treatment of symptomatic multiple myeloma.

Related Articles

Anass Baladi, Hassan Abdelilah Tafenzi, Fatim-Zahra Megzar, Ibrahima Kalil Cisse, Othmane Zouiten, Leila Afani, Ismail Essaadi, Mohammed El Fadli, Rhizlane Belbaraka
Abhijit Shah, Surag KR, Anupam Choudhary, Kasi Viswanath, Krishnakanth AVB, Chaitanya Krishna, Padmaraj Hegde, Gayathri S, Swathi PM
Priti Singh, Chaithanya Leon, Simran Kaur, Atul Batra, Prashant Tayade, Muthukrishnan Suriya Prakash, Ratna Sharma